Updated on 16 October 2026
Clinical Research Partner in Armenia for Neurology and Neurodegenerative Diseases
Deputy Director for Scientific Development at NeuroKlinik – German Center for Neurology in Armenia
Yerevan, Armenia
About
NeuroKlinik is a specialized neurological clinical center based in Yerevan, Armenia, providing neurological diagnostics, treatment and multidisciplinary rehabilitation. Our clinical team includes specialists with extensive training and professional experience in Germany, combining European clinical standards with direct access to neurological patient populations in Armenia.
We are interested in participating as a clinical partner in European and international multicentre research, particularly in neurological and neurodegenerative diseases.
Our main interests include clinical trials of innovative interventions, disease progression, clinical outcomes, prevention, predictive and clinical biomarkers, digital health, and the translation of research findings into clinical practice.
NeuroKlinik can contribute a clinical research setting in Armenia, neurological expertise, access to relevant patient populations, patient recruitment, clinical assessment, neurophysiological evaluation, data collection and follow-up.
We are particularly interested in joining established or developing consortia seeking clinical partners and in contributing Armenia as a clinical research site to European multicentre studies.
Similar opportunities
Project cooperation
- Consortium/Coordinator seeks Partners
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
Dr. Estefanía Ledesma Santiso
CEO at Horizon Europe Leading Projects S.L (HELPEU)
Leon, Spain
Project cooperation
Dental Imaging Data, AI Biomarkers and Clinical Validation – Research Collaboration
- Partner seeks Consortium/Coordinator
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Anda Slaidina
Leading Researcher at Riga Stradiņš University – Faculty of Dentistry
Riga, Latvia
Project cooperation
Quantification of RNA Modification
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Oliver Dening
CEO at TAMASERV GmbH
Mainz, Germany